Exhibit 99.1

SanguiBioTech GmbH and Karl Beese GmbH & Co. plan to jointly distribute
Chitoskin(R) wound pads
-------------------------------------------------------------------------------

Witten, November 16, 2004 - SanguiBioTech GmbH and Beese Medical, one of the
largest German distributors of medical care products and hospital requirements,
will jointly market and distribute Sangui's innovative Chitoskin(R) wound pads
after obtaining the CE mark authorizing the sales of the product in the European
Union. The CE mark certification is about to be completed. The ,,Chitoskin"
brand name was already registered by a German Patent Office certificate of
October 22, 2004. Beese Medical will obtain exclusive Chitoskin(R) marketing
rights in the German market. Sangui and Beese are confident to start marketing
the product in January, 2005. Chitoskin(R) will now be presented jointly on the
Beese stand at MEDICA medical products trade show in Dusseldorf, Germany,
November 24 through 27, 2004.

Gerd Mayer, Beese Medical product manager in charge, said: ,,We are fully
convinced of the extraordinary quality of these innovative wound pads. We plan
to position Chitoskin(R) in the top segment of the market. We strongly believe
that this product will help us gain significant market share in the medium
term." Sangui GmbH Managing Director Hubertus Schmelz added: ,,We are excited to
have won a competent distribution partner who offers the experience, market
position and sales logistics to successfully market our Chitoskin(R) wound pads.
Many medical experts have confirmed already that Chitoskin(R) offers superior
healing quality and with a strong partner like Beese's the market will soon
recognize the potential of this product."

SanguiBioTech GmbH is a wholly owned subsidiary of SanguiBiotech International,
Inc., (NASD OTCBB: SGBIE).

For more information:

Joachim Fleing
Phone: +49 (160) 741 27 17
Fax: +49 (2302) 915 191
e-mail: fleing@sangui.de

This news release includes statements, other than historical fact, that may be
deemed forward-looking. These statements may be accompanied by words such as
"believe," "estimate," "project," "expect," "anticipate," or "predict" that
conveys the uncertainty of future events or outcomes. These statements are based
on assumptions that the Company believes are reasonable; however, many factors
could cause the Company's actual results in the future to differ materially from
the forward-looking statements made herein and in any other documents or oral
presentations made by, or on behalf of, the Company. Important factors which
could cause actual results to differ materially from those in forward-looking
statements include, among others, the ability to obtain additional financing,
which is not assured; rapid technological developments and changes; problems in
developments of the Company's products; price and product competition by
competitors; general economic conditions; and factors discussed in the Company's
SEC filings. Shareholders are cautioned that the forward-looking statements are
not guarantees of future performance and that developments different from those
projected in the forward-looking statements can be expected. Sangui does not
intend (and is not legally obligated) to update publicly any forward-looking
statements.